Drug intelligence / Profile preview

VisuXL

Development stage
Phase 2
Lead developer
Visufarma
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

VisuXL is a preservative-free ophthalmic solution indicated for the treatment of dry eye syndrome and the promotion of ocular surface recovery. It is a combination product containing cross-linked sodium hyaluronate (XL-HA), coenzyme Q10 (CoQ10), and Vitamin E TPGS (tocophersolan). The cross-linked hyaluronic acid provides enhanced mucomimetic and viscoelastic properties compared to standard linear hyaluronic acid, resulting in a longer residence time on the ocular surface and improved lubrication. Coenzyme Q10 serves as a potent antioxidant, protecting corneal cells from oxidative damage and supporting mitochondrial function to aid in corneal wound healing and nerve regeneration. Vitamin E TPGS acts as a surfactant and additional antioxidant that facilitates the delivery of CoQ10. VisuXL is particularly used for moderate to severe dry eye, post-surgical recovery, and ocular surface alterations related to systemic conditions like diabetes.

Brand names
VisuXL
02

Targets

CD44 (CD44 antigen)

Beyond the preview

Go deeper on VisuXL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on VisuXL.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call